Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Informatics

Chemify lands AI drug discovery deal with Dewpoint

by Rick Mullin
September 16, 2023 | A version of this story appeared in Volume 101, Issue 31

 

Chemify and Dewpoint Therapeutics will begin using Chemify’s artificial intelligence and robotics-driven technology to discover and develop molecules that treat cancer and neurodegeneration. Dewpoint itself employs AI along with condensate biology in its discovery research. Under the agreement, Chemify will design and make compounds that Dewpoint may choose to acquire. Chemify will receive unspecified milestone payments and royalties. The UK firm recently raised $43 million in funding.

Article:

This article has been sent to the following recipient:

2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.